Contact Us
Drug Search Results
More Filters [+]

PST-3093

Alternative Names: PST-3093, PST3093, PST 3093
Latest Update: 2024-01-19
Latest Update Note: PubMed Publication

Product Description

PST3093 is the main metabolite of istaroxime, an agent combining Na+/K+ pump inhibition and SERCA2a stimulation, shown by phase 2 trials to be promising in the acute setting. PST3093 half-life is substantially longer than that of istaroxime; therefore, if it retained the effects of the parent compound, it would allow to exploit istaroxime pharmacodynamics in chronic treatment. (Sourced from: https://www.biorxiv.org/content/10.1101/2021.08.17.455204v1)

Mechanisms of Action: SERCA Stimulant

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Windtree
Company Location: WARRINGTON PA 18976
Company CEO: Craig E. Fraser
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PST-3093

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Heart Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

01/19/2024

PubMed

 Selective SERCA2a activator as a candidate for chronic heart failure therapy.

02/28/2023

News Article

 Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure

01/01/2023

PubMed

 Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.

05/26/2022

PubMed

 Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions